E3 ubiquitin-protein ligase CBL

BE0010304ProteinHumansCBL

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567, PubMed:40101708). It is acted on by 1 drug in DrugBank.

Gene name
CBL
UniProtKB entry
P22681Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
906 residues · 99,632 Da
Also known as
2.3.2.27 · Casitas B-lineage lymphoma proto-oncogene · CBL2 · Proto-oncogene c-Cbl · RING finger protein 55

Resolves to

Protein
UniProtP22681UniProt nameCBL_HUMAN
Gene
HGNCHGNC:1541NCBI Gene867GeneCardsCBL
Pharmacology
KEGGhsa:867
Structure
PDB1B47PDB1FBVPDB1YVH
Drugs

What you can answer from here — as of October 30, 2023

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
3Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
8GO termsFunction, process and component, as structured annotations
Sign in
5Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which approved drugs act on E3 ubiquitin-protein ligase CBL, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In